Free Trial
NASDAQ:RIGL

Rigel Pharmaceuticals (RIGL) Stock Price, News & Analysis

Rigel Pharmaceuticals logo
$18.21 +1.06 (+6.18%)
Closing price 04:00 PM Eastern
Extended Trading
$17.02 -1.19 (-6.56%)
As of 06:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Rigel Pharmaceuticals Stock (NASDAQ:RIGL)

Key Stats

Today's Range
$17.15
$18.30
50-Day Range
$17.15
$24.39
52-Week Range
$7.48
$29.82
Volume
204,696 shs
Average Volume
207,730 shs
Market Capitalization
$325.29 million
P/E Ratio
130.08
Dividend Yield
N/A
Price Target
$36.80
Consensus Rating
Hold

Company Overview

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.

Remove Ads

Rigel Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
52nd Percentile Overall Score

RIGL MarketRank™: 

Rigel Pharmaceuticals scored higher than 52% of companies evaluated by MarketBeat, and ranked 442nd out of 930 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Rigel Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 2 buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Rigel Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

  • Read more about Rigel Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Rigel Pharmaceuticals are expected to grow by 377.27% in the coming year, from $0.22 to $1.05 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Rigel Pharmaceuticals is 128.29, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 22.57.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Rigel Pharmaceuticals is 128.29, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 23.61.

  • Read more about Rigel Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    9.03% of the float of Rigel Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Rigel Pharmaceuticals has a short interest ratio ("days to cover") of 5.8.
  • Change versus previous month

    Short interest in Rigel Pharmaceuticals has recently increased by 6.08%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Rigel Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Rigel Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    9.03% of the float of Rigel Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Rigel Pharmaceuticals has a short interest ratio ("days to cover") of 5.8.
  • Change versus previous month

    Short interest in Rigel Pharmaceuticals has recently increased by 6.08%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Rigel Pharmaceuticals has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Rigel Pharmaceuticals this week, compared to 3 articles on an average week.
  • Search Interest

    Only 1 people have searched for RIGL on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
  • MarketBeat Follows

    Only 3 people have added Rigel Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Rigel Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $190,644.00 in company stock.

  • Percentage Held by Insiders

    Only 9.04% of the stock of Rigel Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    66.23% of the stock of Rigel Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Rigel Pharmaceuticals' insider trading history.
Receive RIGL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rigel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RIGL Stock News Headlines

Rigel Pharmaceuticals resolves patent litigation related to Tavalisse
Trump… a socialist?
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
Rigel Pharmaceuticals appoints new board member
See More Headlines

RIGL Stock Analysis - Frequently Asked Questions

Rigel Pharmaceuticals' stock was trading at $16.82 at the start of the year. Since then, RIGL shares have increased by 6.8% and is now trading at $17.96.
View the best growth stocks for 2025 here
.

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) issued its quarterly earnings results on Tuesday, March, 4th. The biotechnology company reported $0.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.30 by $0.50. The biotechnology company had revenue of $57.60 million for the quarter, compared to the consensus estimate of $57.59 million. Rigel Pharmaceuticals had a net margin of 2.46% and a negative trailing twelve-month return on equity of 14.80%.

Shares of Rigel Pharmaceuticals reverse split on Thursday, June 27th 2024. The 1-10 reverse split was announced on Thursday, June 27th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 27th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Shares of RIGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Rigel Pharmaceuticals investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Energy Transfer (ET), SPDR S&P 500 ETF Trust (SPY) and CRISPR Therapeutics (CRSP).

Company Calendar

Last Earnings
3/04/2025
Today
4/02/2025
Next Earnings (Estimated)
5/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:RIGL
Employees
160
Year Founded
1996

Price Target and Rating

Average Stock Price Target
$36.80
High Stock Price Target
$57.00
Low Stock Price Target
$23.00
Potential Upside/Downside
+114.6%
Consensus Rating
Hold
Rating Score (0-4)
2.40
Research Coverage
5 Analysts

Profitability

Trailing P/E Ratio
122.51
Forward P/E Ratio
77.95
P/E Growth
N/A
Net Income
$-25,090,000.00
Pretax Margin
2.46%

Debt

Sales & Book Value

Annual Sales
$179.28 million
Price / Cash Flow
N/A
Book Value
($1.64) per share
Price / Book
-10.46

Miscellaneous

Free Float
16,023,000
Market Cap
$306.35 million
Optionable
Optionable
Beta
1.35

Social Links

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (NASDAQ:RIGL) was last updated on 4/2/2025 by MarketBeat.com Staff
From Our Partners